{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"167"},{"groupId":"OG001","value":"130"}]}],"title":"Grade < 2 Sensory neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"473"},{"groupId":"OG001","value":"534"}]}],"title":"Grade 2 or Higher Sensory Neuropathy"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"29"}]}],"title":"Grade <3 infection with Neutrope"},{"categories":[{"measurements":[{"groupId":"OG000","value":"615"},{"groupId":"OG001","value":"635"}]}],"title":"Grade 3 or Higher Infection with Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"13"}]}],"title":"Grade <3 infection without Neutropenia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"618"},{"groupId":"OG001","value":"651"}]}],"title":"Grade 3 or Higher Infection without Neutropenia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"640"},{"groupId":"OG001","value":"664"}],"units":"Participants"}],"description":"Maximum grade of physician assessed neurotoxicity and infection","groups":[{"description":"Patients receive doxorubicin hydrochloride IV over approximately 15-30 minutes on day 1, cisplatin IV over 60-90 minutes on day 1, paclitaxel IV over 3 hours on day 2, and filgrastim SC on days 3-12 or pegfilgrastim SC on day 3. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I (Doxorubicin Hydrochloride, Cisplatin, Paclitaxel)"},{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 7 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm II (Paclitaxel, Carboplatin)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Eligible and treated patients","reportingStatus":"POSTED","timeFrame":"Assessed throughout the treatment period and for 30 days after discontinuation of treatment.","title":"Number of Participants With Indicated Severity of CTCAE v2 Graded Neurotoxicity and Infection","type":"SECONDARY","unitOfMeasure":"Participants"}